Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Heidi, Whalen"'
Autor:
J. Andrew Bristol, Heidi Whalen, John F. Kokai-Kun, Joseph Sliman, Kenneth C. Lasseter, Olivia Coughlin, Tracey Roberts, Steven Hubert, Barbara Valero Lopez, James Longstreth
Publikováno v:
Clinical Drug Investigation. 36:725-734
SYN-004 is an orally administered β-lactamase enzyme, designed to be given concurrently with certain intravenous β-lactam antibiotics like cephalosporins. SYN-004 is intended to degrade residual antibiotics excreted into the intestine as a result o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e1f60974d01086422b6d69cce43c547
https://doi.org/10.1007/s40261-016-0420-0
https://doi.org/10.1007/s40261-016-0420-0
Autor:
Vincent J. Wacher, Tracey M. Roberts, Olivia Coughlin, Heidi Whalen, John F. Kokai-Kun, Joseph Sliman, Ralph Stevenson, Chenxiong (Charles) Le
Publikováno v:
The Lancet. Infectious diseases. 19(5)
Infections with Clostridium difficile are a health threat, yet no products are currently licensed for prevention of primary C difficile infections. Intravenous β-lactam antibiotics are considered to confer a high risk of C difficile infection becaus
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6337d9ea89986147a7e037836d826697
https://pubmed.ncbi.nlm.nih.gov/30885590
https://pubmed.ncbi.nlm.nih.gov/30885590
Autor:
John F. Kokai-Kun, Tracey M. Roberts, Ralph Stevenson, Joseph Sliman, Vincent J. Wacher, Heidi Whalen, Olivia Coughlin, Chenxiong (Charles) Le
Publikováno v:
SSRN Electronic Journal.
Background: Clostridium difficile infection (CDI) is an urgent public health threat, yet there is no product currently licensed for its prevention. The use of intravenous β-lactam antibiotics are considered high risk for the development of CDI due t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59055f69e51c731ca0c65a13a3d42c48
https://doi.org/10.2139/ssrn.3234882
https://doi.org/10.2139/ssrn.3234882
Autor:
Eric Sicard, Heidi Whalen, Christian Carter, Joseph Sliman, John F. Kokai-Kun, Tracey Roberts, Marijke H. Adams, Marianne Rufiange, Olivia Coughlin, Richard N. Fedorak, James Longstreth
Publikováno v:
Antimicrobial Agents and Chemotherapy
SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam antibiotics, including most penicillins and cephalosporins. Ribaxamase's anticipated mechanism of action is to degrade excess β-lactam
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::701f2262cc280a874750e3fedaefde12
https://doi.org/10.1128/aac.02197-16
https://doi.org/10.1128/aac.02197-16
Autor:
Michael, Liebowitz, Harry A, Croft, Daniel K, Kajdasz, Heidi, Whalen, Susan, Gallipoli, Maria, Athanasiou, Carol R, Reed
Publikováno v:
Psychopharmacology bulletin. 44(3)
Vilazodone is a selective serotonin reuptake inhibitor and 5-HTPooled data from two 8-week, double-blind studies of vilazodone (n = 436) vs placebo (n = 433) and data from one 52-week, open-label study (n = 616, vilazodone only) were analyzed. Patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e7e3ff428b387ee2493b415dea55147d
https://pubmed.ncbi.nlm.nih.gov/27738360
https://pubmed.ncbi.nlm.nih.gov/27738360
Autor:
Susan Gallipoli, Heidi Whalen, Michael E. Thase, Carol R. Reed, Maria Athanasiou, Daniel K. Kajdasz
Publikováno v:
Current Medical Research and Opinion. 28:27-39
Vilazodone is a novel serotonin reuptake inhibitor and serotonin 1A receptor partial agonist approved for the treatment of major depressive disorder (MDD). This evaluation presents side-by-side efficacy data from two randomized, double-blind, placebo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4d608aa9465928ebb719fe5f72a2d0e
https://doi.org/10.1185/03007995.2011.628303
https://doi.org/10.1185/03007995.2011.628303
Autor:
Art Wamil, Susan Gallipoli, Donald S. Robinson, Carol R. Reed, Heidi Whalen, Daniel K. Kajdasz
Publikováno v:
Journal of Clinical Psychopharmacology. 31:643-646
Vilazodone, a selective serotonin (5-HT) reuptake inhibitor and 5-HT(1A) receptor partial agonist, was efficacious in two 8-week placebo-controlled studies in adults with major depressive disorder. This open-label, multicenter study assessed the long
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b62837391288ae3beeb12fa94ed5a7f2
https://doi.org/10.1097/jcp.0b013e31822c6741
https://doi.org/10.1097/jcp.0b013e31822c6741
Autor:
Arif Ullah Khan, Carol R. Reed, Daniel K. Kajdasz, Susan Gallipoli, Donald S. Robinson, Andrew J. Cutler, Heidi Whalen, Maria Athanasiou
Publikováno v:
The Journal of Clinical Psychiatry. 72:441-447
Objective To evaluate the efficacy, and further establish the safety profile, of oral once-daily vilazodone, a potent and selective serotonin 1A receptor partial agonist and reuptake inhibitor, in the treatment of major depressive disorder (MDD). Met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c20dd3d1ba3b676e959a8a8edbc7965
https://doi.org/10.4088/jcp.10m06596
https://doi.org/10.4088/jcp.10m06596
Autor:
Michael Dettling, Kerri A. Pierz, Benjamin A. Salisbury, Ingolf Cascorbi, Carol R. Reed, Heidi Whalen, Maria Athanasiou, Stanton L. Gerson, John M. Kane, Anil K. Malhotra, Wei Zou, Igor Mosyagin, Todd Lencz
Publikováno v:
The Journal of Clinical Psychiatry. 72:458-463
Objective: Clozapine is considered to be the most efficacious drug to treat schizophrenia, although it is underutilized, partially due to a side effect of agranulocytosis. This analysis of 74 candidate genes was designed to identify an association be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d57ff07b165269d88d48f03706c4ef66
https://doi.org/10.4088/jcp.09m05527yel
https://doi.org/10.4088/jcp.09m05527yel
Autor:
Klaus Gottlieb, Tracey Roberts, Joseph Sliman, Eric Sicard, John F. Kokai-Kun, Richard N. Fedorak, Heidi Whalen, Christian Carter, Olivia Coughlin, Marianne Rufiange
Publikováno v:
Open Forum Infectious Diseases. 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a59519d6b1d88c6d4715288faa684309
https://doi.org/10.1093/ofid/ofw172.1060
https://doi.org/10.1093/ofid/ofw172.1060